The FDA has approved Otsuka Pharmaceutical’s ADHD drug Simtriyo, also known as centanafadine, giving the company a new product in the central nervous system space. The treatment is described as a once-daily extended-release capsule.
According to the announcement, Simtriyo is a first-in-class norepinephrine, dopamine and serotonin reuptake inhibitor, or NDSRI. That mechanism sets it apart from more established ADHD medicines and marks the approval as a notable regulatory milestone for Otsuka.
The decision also positions Simtriyo as what the company has called its next major CNS launch. For the Japanese drugmaker, the approval adds momentum to its neuroscience portfolio and opens the door to a commercial rollout in ADHD.
With FDA clearance now secured, attention is likely to shift to how Otsuka introduces Simtriyo in the market and how the first-in-class ADHD therapy fits into the broader treatment landscape. The approval gives physicians and patients another newly authorized option in the category.
